Navigation Links
Signalife Establishes Signalcare Division
Date:2/14/2008

LOS ANGELES, Feb. 14 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) has established a division focused on developing, acquiring and/or testing therapies capable of treating cardiovascular disease at an earlier state and in a more effective manner.

From experience gained and relationships developed through the deployment of its award-winning Fidelity 100 Heart Monitor - including extensive utilization of the Fidelity 100 at this year's Super Bowl in Glendale, Arizona -- the Company has already learned significant details regarding the relationship between earlier and more accurate cardiovascular monitoring, on the one hand, and effective cardiovascular treatment-oriented technologies, on the other hand.

Dr. Lowell Harmison, the Company's President and Chief Executive Officer, commented that "more effective heart monitoring can be used to validate or invalidate technologies that, before now, were unable to be properly vetted. Through the use of our suite of heart monitoring devices and technologies, we believe that it is time to assist in moving the treatment of cardiovascular disease to earlier, less invasive and more predictable methodologies."

The Company has divisionalized Signalcare for the time being, and will evaluate placing Signalcare into a wholly-owned subsidiary after developments and relationships have materialized or have become formalized.

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices, therapies and/or technologies that simplify and reduce the costs of cardiovascular disease. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Signalife to Deploy Fidelity 100 Heart Monitors for AFL
2. LifeNet Health Establishes The Skin & Wound Allograft Institute
3. Carnegie Mellon Establishes Ray and Stephanie Lane Center for Computational Biology
4. AT&T Establishes New Network Services for Leading Medical Liability Insurer
5. Conference on Elephant Tuberculosis Research Establishes Action Plan at International Symposium on Elephant Conservation
6. Sentry Telecare Establishes Partnering Program to Market Telephone Check-in and Personal Emergency Response Service
7. Nunez Health Reform Bill Establishes Mandatory Purchase Without Linking to Subsidies for Middle Class and Poor
8. NxStage Medical Establishes $50 Million Credit Facility with a Group of Lenders Led by Merrill Lynch Capital
9. CIG Corp. Establishes a Medical Advisory Board
10. MM2 Group Establishes New Venture for Sofgel Manufacture in China
11. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... ... with Mediaplanet to help educate the many who are unaware of the plight ... to aphasia will run within the “Stroke Awareness” campaign. , The link between ...
(Date:5/27/2016)... ... ... Aimed at nurses and employees in the health care world, this installment ... nursing and health care industry. It also provides insight to the developing trends and ... As the nursing industry is coming out of one of the biggest recessions in ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting ... and company to wait until March 2017 for an interest rate increase, according to ... College of Business. , “The Federal Open Market Committee (FOMC) dot charts are of ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot ... of defective respirators, according to court documents and SEC filings. A jury ... Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016   ... software and analytics, network solutions and technology-enabled ... announced it entered into a strategic channel ... of outpatient software solutions and revenue cycle ... specialty hospitals and rehabilitation clinics to optimize ...
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
Breaking Medicine Technology: